Nuplazid® (pimavanserin) efficacy data from open-label extension (ole) study published in parkinsonism and related disorders

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced publication of open-label extension (ole) data from patients experiencing hallucinations and delusions associated with parkinson's disease psychosis (pdp) who had previously completed one of three, six-week, double-blind, placebo-controlled studies. the ole efficacy analysis showed that patients previously on nuplazid 34 mg had a sustained efficacy response from week 6 through week 10, and that patients who h
ACAD Ratings Summary
ACAD Quant Ranking